17 Jul Encouraging feedback from key opinion leaders to Immunobiogram in the #TTS2018
Biohope presented BH-Pilot clinical results under the framework of the 27th Congress of the International Society of Transplants (TTS) hold in Madrid from June 30 to July 5, 2018, that brought together more than 3,000 health professionals from around the world related to the field of organ donation and transplantation.
BH-Pilot clinical study has confirmed the usefulness of Immunobiogram to determine the response of immunosuppressive medication in patients who have undergone a kidney transplant, with the participation of 70 patients from the University Hospital La Paz and the University Hospital Puerta de Hierro (both in Madrid, Spain).
Isabel Portero, CEO of Biohope, states that with the information extracted it is possible to detect the patterns of resistance of renal patients to immunosuppressants. «Thanks to the Immunobiogram we can measure the sensitivity and resistance of each patient to the most common immunosuppressive treatments, detecting those with an expected worse response. When clinical validation studies are completed, doctors will be able to use it to consider alternative ways of adjusting the treatment according to the results obtained, selecting the most adequate drugs and doses, thus facilitating informed decision-making in clinical practice for minimize the risk of rejection in kidney transplants.»
«Only a conventional blood sample is needed to perform the test. The data is analyzed, and its result is integrated into software that provides the degree of sensitivity of the patient’s immune cells to the most recommended treatments in the clinical guidelines « explains Dr. Portero.
During the Lunch&Learn session organized by Biohope, Dr. Julio Pascual, Chief Nephrology Department and Kidney Transplantation Program in the Hospital del Mar (Barcelona, Spain) and coordinator of the TRANSBIO clinical study, shown his thoughts about the BH-Pilot results and the possibilities of Immunobiogram for the management of kidney transplanted patients.
«With the aim of confirming these data, Biohope have launched TRANSBIO, a multi-center international study involving several hospitals from Europe and US, and that will allow us to verify the clinical usefulness of the Immunobiogram and its accuracy in a wider sample of patients» says Dr. Pascual, who continues affirming that «to corroborate the results, the Immunobiogram could become a great support for therapeutic decision making in these patients in clinical practice»
Several European key opinion leaders in the field of nephrology attended to this session: Dr. Marta Crespo Barrio, Dept. of Nephrology, Hospital del Mar (Barcelona, Spain); Dr. José María Portolés, Dept. of Nephrology. University Hospital Puerta de Hierro (Mahadahonda, Madrid, Spain); Dr. Carlos Jiménez Martín, Dept. of Nephrology, University Hospital La Paz (Madrid, Spain); Dr. Daniel Seron Micas and Dr. Francesc Josep Moreso Mateos, Dept. of Nephrology, Vall d’Hebron Hospital (Barcelona, Spain); Dr. Dorota Kamińska and Miroslaw Banasik, Dept. of Nephrology and Transplantation Medicine, Wroclaw Medical University (Wrocław, Polonia); Dr. Klemens Budde, Head of Department of Nephrology, Charité Universitätsmedizin (Berlin, Germany); Dr. Maarten Naesens, Department of Nephrology and Renal Transplantation, University Hospitals Leuven (Leuven, Belgium); Dr. Christophe Legendre, Head of the Adult Nephrology and Transplantation Unit at Necker Hospital (Paris, France).
All of them expressed the current clinical need for a personalization treatment tool as Immunobiogram and gave a positive feedback to the data shown in the workshop.